Alector Inc
ALEC
Company Profile
Business description
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Contact
131 Oyster Point Boulevard
Suite 600
South San FranciscoCA94080
USAT: +1 415 231-5660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
103
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,040.80 | 15.00 | 0.17% |
| CAC 40 | 8,508.07 | 33.21 | 0.39% |
| DAX 40 | 25,779.31 | 198.43 | 0.78% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,679.03 | 26.16 | 0.25% |
| HKSE | 23,350.03 | 295.00 | 1.28% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,671.77 | 72.30 | -0.10% |
| NZX 50 Index | 13,695.33 | 76.91 | 0.56% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,834.00 | 15.70 | 0.18% |
| SSE Composite Index | 4,043.64 | 14.74 | 0.37% |